表皮生长因子受体
表皮生长因子受体抑制剂
癌症
靶向治疗
癌症研究
酪氨酸激酶
医学
受体
内科学
作者
Adileh Ayati,Setareh Moghimi,Somayeh Salarinejad,Maliheh Safavi,Behjat Pouramiri,Alireza Foroumadi
标识
DOI:10.1016/j.bioorg.2020.103811
摘要
The identification of molecular agents inhibiting specific functions in cancer cells progression is considered as one of the most successful plans in cancer treatment. The epidermal growth factor receptor (EGFR) over-activation is observed in a vast number of cancers, so, targeting EGFR and its downstream signaling cascades are regarded as a rational and valuable approach in cancer therapy. Several synthetic EGFR tyrosine kinase inhibitors (TKIs) have been evaluated in recent years, mostly exhibited clinical efficacy in relevant models and categorized into first, second, third and fourth-generation. However, studies are still ongoing to find more efficient EGFR inhibitors in light of the resistance to the current inhibitors. In this review, the importance of targeting EGFR signaling pathway in cancer therapy and related epigenetic mutations are highlighted. The recent advances on the discovery and development of different EGFR inhibitors and the use of various therapeutic strategies such as multi-targeting agents and combination therapies have also been reviewed.
科研通智能强力驱动
Strongly Powered by AbleSci AI